2/9
08:58 am
inab
IN8bio promotes COO to president & COO [Seeking Alpha]
Low
Report
IN8bio promotes COO to president & COO [Seeking Alpha]
2/9
08:00 am
inab
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
Low
Report
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
2/3
08:00 am
inab
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
Low
Report
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
1/24
05:08 am
inab
IN8bio (NASDAQ:INAB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
IN8bio (NASDAQ:INAB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
1/17
06:56 am
inab
IN8bio (NASDAQ:INAB) was upgraded by analysts at Zacks Research to a "hold" rating.
Medium
Report
IN8bio (NASDAQ:INAB) was upgraded by analysts at Zacks Research to a "hold" rating.
1/12
08:55 am
inab
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma [Yahoo! Finance]
Medium
Report
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma [Yahoo! Finance]
1/12
08:00 am
inab
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
High
Report
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
12/19
08:35 am
inab
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager [Yahoo! Finance]
High
Report
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager [Yahoo! Finance]
12/19
08:00 am
inab
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
High
Report
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager